16.23

2.99% -0.50

After Hours: 16.25 0.02 +0.12%

Bausch Lomb Corp (BLCO)

Overview News Price History Option Chain Financials Discussions Forecast

Bausch Lomb Corp stock is traded at $16.23, with a volume of 256.59K. It is down -2.99% in the last 24 hours and up +6.36% over the past month. Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Previous Close:

$16.73

Open:

$16.68

24h Volume:

256.59K

Relative Volume:

0.59

Market Cap:

$5.79B

Revenue:

$5.21B

Net Income/Loss:

$-211.00M

P/E Ratio:

-26.27

EPS:

-0.6179

Net Cash Flow:

$861.30K

1W Performance:

-5.42%

1M Performance:

+6.36%

6M Performance:

-5.69%

1Y Performance:

+14.30%

1-Day Range:

$15.98

$16.77

1-Week Range:

$15.98

$17.46

52-Week Range:

$13.09

$18.91

Bausch Lomb Corp Stock (BLCO) Company Profile

Name

Bausch Lomb Corp

Sector

Healthcare (1096)

Industry

Medical Instruments & Supplies (56)

Phone

908-541-5456

Address

520 APPLEWOOD CRESCENT, VAUGHAN

Employee

13,000

Twitter

Next Earnings Date

2026-07-29

Latest SEC Filings

BLCO's Discussions on Twitter

Compare BLCO vs ISRG, BDX, MDLN, ALC, RMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BLCO Bausch Lomb Corp	16.23	5.96B	5.21B	-211.00M	861.30K	-0.6179
ISRG Intuitive Surgical Inc	406.78	145.76B	10.58B	3.00B	2.83B	8.2437
BDX Becton Dickinson Co	151.94	41.57B	21.37B	1.41B	3.07B	3.9437
MDLN Medline Inc	41.04	34.54B	29.14B	1.07B	1.05B	1.1956
ALC Alcon Inc	67.81	32.74B	10.63B	819.00M	1.59B	1.6577
RMD Resmed Inc	203.87	30.24B	5.54B	1.52B	1.74B	10.37

Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line
Dec-11-25	Upgrade	Citigroup	Neutral → Buy
Dec-02-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-01-25	Initiated	Goldman	Neutral
May-02-25	Reiterated	H.C. Wainwright	Buy
Mar-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Dec-02-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-15-24	Upgrade	Evercore ISI	In-line → Outperform
Jul-10-24	Initiated	Raymond James	Outperform
May-06-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-04-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-12-23	Initiated	Stifel	Hold
Oct-03-23	Resumed	Evercore ISI	Outperform
May-30-23	Resumed	Morgan Stanley	Equal-Weight
Mar-09-23	Initiated	Needham	Hold
Dec-21-22	Initiated	Barclays	Equal Weight
Sep-12-22	Initiated	H.C. Wainwright	Buy
Jul-26-22	Initiated	RBC Capital Mkts	Outperform
Jun-24-22	Initiated	Evercore ISI	Outperform
Jun-06-22	Initiated	Citigroup	Buy
May-31-22	Initiated	Deutsche Bank	Hold
May-31-22	Initiated	Goldman	Neutral
May-31-22	Initiated	Guggenheim	Buy
May-31-22	Initiated	JP Morgan	Neutral
May-31-22	Initiated	Jefferies	Buy
May-31-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Initiated	Wells Fargo	Overweight
May-11-22	Initiated	Cowen	Outperform

View All

Bausch Lomb Corp Stock (BLCO) Latest News

05:27 AM

Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today - Yahoo Finance

05:27 AM

10:23 AM

Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Benzinga

10:23 AM

07:37 AM

Price to earnings forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView

07:37 AM

04:52 AM

Price to sales forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView

04:52 AM

03:57 AM

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - BioSpace

03:57 AM

02:34 AM

Bausch + Lomb abandons glaucoma drops after phase 2 failure - MSN

02:34 AM

02:11 AM

Bausch + Lomb (BLCO) Could Be 57% Below Fair Value After Product Updates - Yahoo Finance

02:11 AM

12:27 PM

Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform - VisionMonday.com

12:27 PM

Jul 09, 2026

Bausch + Lomb halts glaucoma eye drop program after trial miss By Investing.com - Investing.com South Africa

Jul 09, 2026

BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits

Jul 09, 2026

Bausch + Lomb Ends Glaucoma Eye-Drop Development After Missed Trial Endpoint - Moomoo

Jul 09, 2026

Bausch + Lomb introduces Orphia, an AI-powered digital health platform - Chain Drug Review

Jul 09, 2026

Bausch + Lomb launches AI-powered digital health platform By Investing.com - Investing.com Canada

Jul 09, 2026

Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care - marketscreener.com

Jul 09, 2026

Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo

Jul 09, 2026

Jul 06, 2026

Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29 - BioSpace

Jul 06, 2026

Bausch + Lomb Corp updates keep long-term strategy in focus - ad-hoc-news.de

Jul 06, 2026

Press Release: Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29 - Moomoo

Jul 06, 2026

Bausch + Lomb launches Bi-Blade+ vitrectomy cutter in Europe - Investing.com

Jul 06, 2026

(BLCO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Jul 06, 2026

Bausch + Lomb Survey Finds That Addressing Dry Eye Symptoms Boosts Confidence, Lowers Anxiety - VisionMonday.com

Jul 06, 2026

Jul 05, 2026

BLCOBausch + Lomb Corp Volatility & Greeks - Finviz

Jul 05, 2026